中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 12
Dec.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(12): 2843-2848

Global research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on CiteSpace analysis

DOI: 10.3969/j.issn.1001-5256.2021.12.022
  • 1.

    Key Laboratory, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

  • 2a.

    State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

  • 2b.

    Office of Academic Research, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

  • 3.

    Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China

Research funding:

National Natural Science Foundation of China (81773170)

  • Received Date: 2021-05-10
  • Accepted Date: 2021-06-15
  • Published Date: 2021-12-20
    Abstract
  •   Objective  To investigate the research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on bibliometric methods.  Methods  The Web of Science-SCI Expanded database was searched with the following search strategy: #1 TS = (Liver Neoplasms OR Neoplasms, Hepatic OR Neoplasms, Liver OR Liver Neoplasm OR Neoplasm, Liver OR Hepatic Neoplasms OR Hepatic Neoplasm OR Neoplasm, Hepatic OR Cancer of Liver OR Hepatocellular Cancer OR Cancers, Hepatocellular OR Hepatocellular Cancers OR Hepatic Cancer OR Cancer, Hepatic OR Cancers, Hepatic OR Hepatic Cancers OR Liver Cancer OR Cancer, Liver OR Cancers, Liver OR Liver Cancers OR Cancer of the Liver OR Cancer, Hepatocellular) AND #2 TS = (Immunotherapy OR Immunotherapies OR Immunity therapy); time span: 2011-2020; type of literature: Article; language: English. CiteSpace software was used to perform a visualized analysis of the articles in the field of immunotherapy for liver cancer published in 2011-2020 from the aspects of the distributions of year, country, institution, author, journal, and fund, times cited, and keywords, and the frequency, centrality, and clustering of keywords were discussed.  Results  A total of 1972 articles on immunotherapy for liver cancer were included, and the analysis showed that China was the country with the largest number of articles, Sun Yat-sen University was the institution with the largest number of articles, and Journal for Immunotherapy of Cancer was the journal with the largest number of articles. The research hotspots in this field included tumor-associated macrophages, oncolytic virus (such as adenovirus), tumor vaccine therapy, adoptive cellular immunotherapy, immune checkpoint inhibitors, and combined immunotherapy. The trend of this field was tumor vaccine therapy → immunotherapy for oncolytic virus → adoptive cellular immunotherapy → immune checkpoint inhibitor therapy.  Conclusion  Immunotherapy for liver cancer has undergone continuous development in the recent ten years, and with the research and development of tumor vaccine therapy, oncolytic virus, and immune checkpoint inhibitors and the improvement of immune checkpoint inhibitors, combined treatment based on immunotherapy is expected to further improve the clinical outcome of liver cancer.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    SUN KX, ZHENG RS, ZHANG SW, et al. Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.

    孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
    [2]
    YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.

    袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
    [3]
    HOLLEBECQUE A, MALKA D, FERTÉ C, et al. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons[J]. Eur J Cancer, 2015, 51(3): 327-339. DOI: 10.1016/j.ejca.2014.12.005.
    [4]
    LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.

    梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.
    [5]
    YAO L, HUI L, YANG Z, et al. Freshwater microplastics pollution: Detecting and visualizing emerging trends based on Citespace Ⅱ[J]. Chemosphere, 2020, 245: 125627. DOI: 10.1016/j.chemosphere.2019.125627.
    [6]
    MURRAY AG, WARDEH M, MCINTYRE KM. Using the H-index to assess disease priorities for salmon aquaculture[J]. Prev Vet Med, 2016, 126: 199-207. DOI: 10.1016/j.prevetmed.2016.02.007.
    [7]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [8]
    NAKAMOTO Y, MIZUKOSHI E, KITAHARA M, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J]. Clin Exp Immunol, 2011, 163(2): 165-177. DOI: 10.1111/j.1365-2249.2010.04246.x.
    [9]
    HUANG H, LIU Y, LIAO W, et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy[J]. Nat Commun, 2019, 10(1): 4801. DOI: 10.1038/s41467-019-12794-2.
    [10]
    ROSEWELL SHAW A, SUZUKI M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment[J]. Front Immunol, 2018, 9: 2103. DOI: 10.3389/fimmu.2018.02103.
    [11]
    WANG Y, YANG X, YU Y, et al. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells[J]. J Cancer, 2018, 9(2): 275-287. DOI: 10.7150/jca.22176.
    [12]
    KOJIMA Y, VOLKMER JP, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016, 536(7614): 86-90. DOI: 10.1038/nature18935.
    [13]
    BARKAL AA, WEISKOPF K, KAO KS, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy[J]. Nat Immunol, 2018, 19(1): 76-84. DOI: 10.1038/s41590-017-0004-z.
    [14]
    SANGRO B, GOMEZ-MARTIN C, de la MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013, 59(1): 81-88. DOI: 10.1016/j.jhep.2013.02.022.
    [15]
    LEE MS, RYOO BY, HSU CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140): Anopen-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6): 808-820. DOI: 10.1056/NEJMoa1915745.
    • Relative Articles
    • Supplements(1)
  • 12期单独排.pdf
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (465) PDF downloads(46) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return